Menu
P95's Journey From Epidemiology Consulting to Comprehensive CRO
In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).
Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.
“In addition to COVID, there is an astounding need for vaccines to treat infectious diseases on a global scale, such as RSV, influenza, HMPV, and fast-spreading Dengue in and around South America. The demand has no limit, and P95 is ready to rise to the challenge and meet this need.” – Thomas Verstaeten, P95 CEO
“Large-scale CROs often lack the necessary specialization and agility required to support the intense demand for clinical vaccine development. P95, with its reputation for deep expertise and flexibility in providing customized client services, stands out in this landscape.” – Benoit Bouche, P95 Chairman
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors.